GW Henssler & Associates’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-3,382
| Closed | -$375K | – | 240 |
|
|
2025
Q2 | $375K | Hold |
3,382
| – | – | 0.02% | 139 |
|
|
2025
Q1 | $379K | Sell |
3,382
-188,811
| -98% | -$19.5M | 0.02% | 130 |
|
|
2024
Q4 | $16.1M | Sell |
192,193
-2,355
| -1% | -$212K | 0.92% | 51 |
|
|
2024
Q3 | $16.3M | Sell |
194,548
-4,450
| -2% | -$340K | 0.92% | 50 |
|
|
2024
Q2 | $13.7M | Buy |
198,998
+2,442
| +1% | +$163K | 0.82% | 54 |
|
|
2024
Q1 | $14.4M | Buy |
196,556
+3,176
| +2% | +$244K | 0.85% | 54 |
|
|
2023
Q4 | $15.7M | Sell |
193,380
-2,329
| -1% | -$181K | 1.03% | 45 |
|
|
2023
Q3 | $14.7M | Sell |
195,709
-946
| -0.5% | -$72.8K | 1% | 48 |
|
|
2023
Q2 | $15.2M | Buy |
196,655
+337
| +0.2% | +$26.9K | 1% | 47 |
|
|
2023
Q1 | $16.3M | Sell |
196,318
-2,813
| -1% | -$233K | 1.08% | 44 |
|
|
2022
Q4 | $17.1M | Sell |
199,131
-1,344
| -0.7% | -$106K | 1.2% | 38 |
|
|
2022
Q3 | $12.4M | Buy |
200,475
+26,479
| +15% | +$1.67M | 0.93% | 49 |
|
|
2022
Q2 | $10.8M | Sell |
173,996
-19,409
| -10% | -$1.2M | 0.8% | 53 |
|
|
2022
Q1 | $11.5M | Buy |
193,405
+10,657
| +6% | +$681K | 0.7% | 56 |
|
|
2021
Q4 | $13.3M | Buy |
182,748
+1,448
| +0.8% | +$99.7K | 0.85% | 50 |
|
|
2021
Q3 | $12.7M | Sell |
181,300
-11,310
| -6% | -$795K | 0.88% | 54 |
|
|
2021
Q2 | $13.3M | Buy |
192,610
+5,320
| +3% | +$355K | 0.87% | 53 |
|
|
2021
Q1 | $12.1M | Buy |
187,290
+42,050
| +29% | +$2.71M | 0.87% | 56 |
|
|
2020
Q4 | $8.46M | Sell |
145,240
-34,131
| -19% | -$2.06M | 0.65% | 60 |
|
|
2020
Q3 | $11.3M | Buy |
179,371
+2,025
| +1% | +$140K | 0.96% | 51 |
|
|
2020
Q2 | $13.6M | Sell |
177,346
-6,227
| -3% | -$477K | 1.2% | 39 |
|
|
2020
Q1 | $13.7M | Buy |
183,573
+2,978
| +2% | +$206K | 1.39% | 33 |
|
|
2019
Q4 | $11.7M | Sell |
180,595
-2,566
| -1% | -$167K | 0.97% | 44 |
|
|
2019
Q3 | $11.6M | Buy |
183,161
+1,004
| +0.6% | +$65.6K | 1.03% | 42 |
|
|
2019
Q2 | $12.3M | Buy |
182,157
+1,708
| +0.9% | +$112K | 1.11% | 38 |
|
|
2019
Q1 | $11.7M | Buy |
180,449
+20,240
| +13% | +$1.35M | 1.08% | 42 |
|
|
2018
Q4 | $10M | Sell |
160,209
-17,665
| -10% | -$1.23M | 1.07% | 40 |
|
|
2018
Q3 | $13.7M | Buy |
177,874
+2,301
| +1% | +$174K | 1.25% | 34 |
|
|
2018
Q2 | $12.4M | Buy |
175,573
+4,769
| +3% | +$337K | 1.22% | 36 |
|
|
2018
Q1 | $12.9M | Buy |
170,804
+334
| +0.2% | +$26.6K | 1.29% | 31 |
|
|
2017
Q4 | $12.2M | Buy |
170,470
+3,414
| +2% | +$259K | 1.14% | 39 |
|
|
2017
Q3 | $13.5M | Buy |
167,056
+6,547
| +4% | +$501K | 1.36% | 24 |
|
|
2017
Q2 | $11.4M | Buy |
160,509
+11,880
| +8% | +$791K | 1.18% | 34 |
|
|
2017
Q1 | $10.1M | Buy |
+148,629
| New | +$10.5M | 1.09% | 41 |
|
Other funds holding GILD
GW Henssler & Associates's GILD Position: Q3 2025 in Review
GW Henssler & Associates sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 3,382 shares — an estimated $375K sold.
GW Henssler & Associates first reported a position in GILD in Q1 2017 and held it in 34 quarters. The position peaked at $17.1M in Q4 2022. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.
- GW Henssler & Associates reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
- GW Henssler & Associates sold 3,382 Gilead Sciences shares in Q3 2025, an estimated $375K.
- GW Henssler & Associates first reported a position in Gilead Sciences in Q1 2017 and held it in 34 quarters.
- GW Henssler & Associates's Gilead Sciences position peaked at $17.1M in Q4 2022.
- 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.
Based on GW Henssler & Associates's 13F filing for Q3 2025, filed 23 Jan 2026.